During the past decade, Vitamed conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vitamed" #1 collaborator was "Biofortis Mérieux NutriSciences" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Vitamed" are "Diabetes type2" (1 trials), "Dysglycemia" (1 trials), "Gastroparesis" (1 trials), "Influenza" (1 trials) and "Prediabetic State" (1 trials). Many other conditions were trialed in "Vitamed" in a lesser frequency.

Most popular intervention types in "Vitamed" are "Drug" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Interferon beta-1a" (1 trials), "Interferon beta-1a-matching placebo" (1 trials), "Ocrelizumab" (1 trials), "Ocrelizumab-matching placebo" (1 trials) and "Placebo 3 intakes per day" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vitamed" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Vitamed". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Vitamed, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Vitamed, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".